AbbVie's lutikizumab meets Phase 3 endpoints in hidradenitis suppurativa, but analysts expected more
- AbbVie reported late-stage results for lutikizumab, its skin disease candidate, with the trial meeting multiple endpoints and reducing abscess burden.
- Some analysts called the data disappointing, raising questions about the drug's commercial prospects.
- The company is eyeing regulatory filings in 2027.
💡 Points
A 2027 filing target despite a lukewarm readout suggests AbbVie sees lutikizumab as a pipeline-refill play, not a breakout. Hidradenitis suppurativa is crowded with established IL-17 options, so hitting endpoints without clearly beating them leaves differentiation thin. With Humira erosion ongoing, AbbVie likely values a dermatology follow-on even at modest peak sales.
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations ↗